BHO Expected wait times for access to a disease-modifying Alzheimer’s treatment in England: A modelling study November 6, 2023
BHO Expected and diagnosed rates of mild cognitive impairment and dementia in the U.S. Medicare population: observational analysis July 22, 2023
BHO Blood-based biomarkers for Alzheimer’s disease: Current state and future use in a transformed global healthcare landscape June 8, 2023
BHO Preparedness of China’s health care system to provide access to a disease-modifying Alzheimer’s treatment June 6, 2023
BHO Expanding the use of brief cognitive assessments to detect suspected early-stage cognitive impairment in primary care April 19, 2023
BHO A framework for addressing Alzheimer’s disease: Without a frame, the work has no aim December 8, 2022
BHO Improving community health-care systems’ early detection of cognitive decline and dementia October 31, 2022
BHO Blood Biomarkers from Research Use to Clinical Practice: What Must Be Done? A Report from the EU/US CTAD Task Force October 16, 2022
